478336-92-4 Usage
Uses
1. Used in Anti-Inflammatory Applications:
MIF Antagonist, ISO-1 is used as an anti-inflammatory agent for its ability to suppress the production of pro-inflammatory cytokines and mediators, such as TNFα, PGE2, and COX-2, in human monocytes and arachidonic acid in RAW 264.7 macrophages. This makes it a promising candidate for the treatment of various inflammatory conditions.
2. Used in Sepsis Treatment:
MIF Antagonist, ISO-1 is used as a therapeutic agent for severe sepsis, as it has been shown to increase survival rates in affected patients. Its anti-inflammatory properties help in mitigating the harmful effects of excessive inflammation during sepsis.
3. Used in Asthma Treatment:
MIF Antagonist, ISO-1 is used as a potential treatment for asthma, as it has been demonstrated to inhibit airway remodeling in a mouse asthma model. This suggests that ISO-1 could be a valuable addition to current asthma treatment strategies.
4. Used in Diabetes Treatment:
MIF Antagonist, ISO-1 is used as an antidiabetogenic agent in the context of immunoinflammatory diabetic mouse models. Its ability to modulate immune responses and reduce inflammation may contribute to improved glycemic control and overall diabetes management.
5. Used in Autophagy Research:
MIF Antagonist, ISO-1 is used as a research tool for studying the role of MIF-induced autophagy in various cellular processes and disease states. By blocking MIF-induced autophagy, ISO-1 can help researchers better understand the underlying mechanisms and potential therapeutic targets for autophagy-related conditions.
6. Used in Pharmaceutical Industry:
MIF Antagonist, ISO-1 is used as a lead compound for the development of novel anti-inflammatory and immunomodulatory drugs. Its multifaceted effects on inflammation, autophagy, and immune responses make it a valuable starting point for designing new therapeutic agents targeting a range of diseases and conditions.
References
1) Al-Abed et al. (2005), ISO-1 binding to the tautomerase active site of MIF inhibits its pro-inflammatory activity and increases survival in severe sepsis; J. Biol. Chem., 280
2) Chen et al. (2010), ISO-1, a macrophage migration inhibitory factor antagonist, inhibits airway remodeling in a murine model of chronic asthma; Mol. Med., 16 400
3) Chuang et al. (2012), Macrophage migration inhibitory factor induces autophagy via reactive oxygen species generation; PLoS One, 7 e37613
Check Digit Verification of cas no
The CAS Registry Mumber 478336-92-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,7,8,3,3 and 6 respectively; the second part has 2 digits, 9 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 478336-92:
(8*4)+(7*7)+(6*8)+(5*3)+(4*3)+(3*6)+(2*9)+(1*2)=194
194 % 10 = 4
So 478336-92-4 is a valid CAS Registry Number.
478336-92-4Relevant academic research and scientific papers
Synthesis and bio-evaluation of human macrophage migration inhibitory factor inhibitor to develop anti-inflammatory agent
Alam, Athar,Pal, Chinmay,Goyal, Manish,Kundu, Milan Kumar,Kumar, Rahul,Iqbal, Mohd Shameel,Dey, Sumanta,Bindu, Samik,Sarkar, Souvik,Pal, Uttam,Maiti, Nakul C.,Adhikari, Susanta,Bandyopadhyay, Uday
, p. 7365 - 7373 (2012/01/06)
Macrophage migration inhibitory factor (MIF), a pro-inflammatory cytokine, is involved in the development of an array of inflammatory disorders including rheumatoid arthritis, inflammatory bowel disease, psoriasis, multiple sclerosis and sepsis. The synthesis of MIF-inhibitor is a rationale approach to develop novel anti-inflammatory agent to treat multitude of inflammatory diseases. In this work, we have synthesized and evaluated MIF-inhibitory activity of a series of small molecules containing isoxazoline skeleton. Mode of binding of this inhibitor to human MIF (huMIF) was determined by docking studies. The synthesized molecules inhibit tautomerase activity of huMIF. The anti-inflammatory activity of the most active inhibitor, 4-((3-(4-hydroxy-3- methoxyphenyl)-4, 5-dihydroisoxazol-5-yl) methoxy) benzaldehyde (4b) was evaluated against huMIF-induced inflammation in a cellular model (RAW 264.7 cell). Compound 4b significantly inhibits huMIF-mediated NF-κB translocation to the nucleus, up-regulation of inducible nitric oxide synthase and nitric oxide production in RAW 264.7 cell which are the markers for inflammation. The compound 4b is not cytotoxic as evident from cell viability assay. Hence, the compound 4b has potential to be a novel anti-inflammatory agent.
Δ2-isoxazolines from β,γ-unsaturated oximes
Mosher, Michael D.,Emmerich, Laura G.,Frost, Katherine S.,Anderson, Benjamin
, p. 535 - 539 (2007/10/03)
3,5-Disubstituted Δ2-isoxazolines can be prepared using the palladium-mediated nucleometalation/ methoxycarbonylation of β,γ-unsaturated oximes. This novel route to this class of compounds is tolerant of a wide variety of functionality in the s
